ALX Oncology Announces Pricing of Initial Public Offering
17 Luglio 2020 - 2:39AM
ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage
immuno-oncology company developing therapies that block the CD47
checkpoint pathway, today announced the pricing of its initial
public offering of 8,500,000 shares of its common stock at a public
offering price of $19.00 per share. All of the shares are being
offered by ALX Oncology. The gross proceeds of the offering, before
deducting underwriting discounts and commissions and other offering
expenses payable by ALX Oncology, are expected to be $161.5
million. The shares are expected to begin trading on the Nasdaq
Global Market on July 17, 2020, under the ticker symbol “ALXO.” The
offering is expected to close on July 21, 2020, subject to the
satisfaction of customary closing conditions. In addition, ALX
Oncology has granted the underwriters a 30-day option to purchase
up to an additional 1,275,000 shares of common stock at the initial
public offering price, less the underwriting discounts and
commissions.
Jefferies, Credit Suisse, Piper Sandler and Cantor are acting as
joint book-running managers for the offering. LifeSci Capital is
acting as lead manager for the offering.
Registration statements relating to these securities became
effective on July 16, 2020. The offering will be made only by means
of a prospectus, copies of which may be obtained from Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by telephone at (877)
821-7388, or by email at prospectus_department@Jefferies.com;
Credit Suisse Securities (USA) LLC, Attention: Prospectus
Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by
telephone at (800) 221-1037, or by email
at usa.prospectus@credit-suisse.com; Piper Sandler & Co.,
Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by
email at prospectus@psc.com; or Cantor Fitzgerald & Co.,
Attention: Capital Markets, 499 Park Avenue, 6th
Floor New York, New York 10022, or by email
at prospectus@cantor.com. Copies of the final prospectus, when
available, related to the offering will be available at
www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company focused
on helping patients fight cancer by developing therapies that block
the CD47 checkpoint pathway and bridge the innate and adaptive
immune system. ALX Oncology’s lead product candidate, ALX148, is a
next generation CD47 blocking therapeutic that combines a
high-affinity CD47 binding domain with an inactivated, proprietary
Fc domain. ALX148 has demonstrated promising clinical responses
across a range of hematologic and solid malignancies in combination
with a number of leading anti-cancer agents. ALX Oncology intends
to advance ALX148 into clinical development for the treatment of
myelodysplastic syndromes and to continue clinical development for
the treatment of a range of solid tumor indications.
Media Contact
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
Investor Contact
Peter Garcia
CFO, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Lug 2023 a Lug 2024